![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » DEBIOPHARM AND DEVELOGEN ANNOUNCE PARTNERING OF MYASTHENIA GRAVIS PROGRAM
DEBIOPHARM AND DEVELOGEN ANNOUNCE PARTNERING OF MYASTHENIA GRAVIS PROGRAM
August 17, 2005
Debiopharm S.A., the independent drug development company specialising in oncology, endocrinology and niche products and DeveloGen AG, a biopharmaceutical company focusing on novel treatments for metabolic disorders, today announced an exclusive worldwide collaboration and licensing agreement, by which Debiopharm will develop PTR-262, a novel peptide drug for the treatment of myasthenia gravis (MG), before out-licensing to global partners for commercialisation.
Yahoo News (http://biz.yahoo.com/prnews/050816/uktu003.html?.v=24)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct